Tachyon Ventures
Venture capitalLos Angeles · Pre-Seed–Series A · 2 people tracked
Investment thesis
Tachyon focuses on early-stage investment in disruptive scientific platforms across biology and medicine. The firm believes it can price scientific risk earlier than others by identifying strong science early and assessing its potential across development stages. It maximizes upside by backing disruptive platforms early while mitigating risk through a focus on world-class research with protected intellectual property. Tachyon backs teams with world-leading published research who are recognized leaders in their fields, and invests in companies with protected IP developed by or in collaboration with their scientific co-founders. It draws on a network of knowledgeable scientists at top research institutions.
Source: firm website, verified Aug 3, 2026.
Team · 2 people
from public directories
What they invest in
from 16 of 18 portfolio companiesBiotech ×16Medical Devices ×9Healthtech ×7Deep Tech ×6AI & Machine Learning ×4Digital Health ×4
HQs:United States×10
Investments · 18 tracked
founders shown can be your intro pathBy year:2024 · 22021 · 13 dated
Absci is a generative AI drug creation company that uses its Integrated Drug Creation platform, combining AI models and wet-lab validation, to design biologics against difficult-to-drug targets.
AI & Machine LearningBiotechDeep TechPortland, US
Sean McClain(Executive Officer)Phil Barish(Executive Officer)
BoardZach Jonasson(Director)Daniel Gold(Director)Bryan Lawlis(Director)
Co-investorsDas & Co.Oregon Venture FundPhoenix Venture PartnersTau VenturesBiotechnology Value FundCasdin Capital+2 more
AI Proteins designs engineered miniproteins for drug discovery and development in the biopharmaceutical industry.
AI & Machine LearningBiotechDeep TechAndover, US
Chris Bahl(Executive Officer, Director)Dominique Verhelle(Director)Bill McKee(Director)Julia Novina(Executive Officer)Marc A. Cohen(Executive Officer, Director)inGeoff Meyerson(Director)
Co-investorsMission BiocapitalCobro Ventures
Altay Therapeutics develops small molecule inhibitors targeting transcription factors to treat serious diseases including facioscapulohumeral muscular dystrophy and cancer.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Ali Ozes(Founder)inOsman Ozes(Founder)in
Co-investorsCreative Destruction Lab (CDL)Y Combinator
Axonis Therapeutics is a drug discovery company developing first-in-class therapies for currently incurable neurological disorders.
BiotechDeep TechHealthtechMedical DevicesBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)Jeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso VenturesLumira VenturesPathway Bioventures+6 more
BiotechBerkeley, US
Genine A. Winslow(Executive Officer, Director)Ran Geng(Director)Winnie Wan(Director)
Co-investorsBerkeley SkyDeck FundFuture Planet CapitalSolasta Ventures
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Anthony DePasqua(Executive Officer, Director)inJason Camm(Director)Kasper Roet(Director)Tony DePasqua(President & CEO)Kevin Kalish(COO)Marcie Glicksman(VP Biology)
Co-investors20/20 HealthCare Partners LLCFlucas VenturesVU Venture PartnersDolby Family Ventures
EpiBone engineers bone tissue from stem cells for regenerative medicine and clinical reconstruction, serving patients requiring bone grafts or craniofacial repair.
BiotechHealthtechMedical DevicesNew York, US
Nina Tandon(Co-Founder, CEO)Sarindr Bhumiratana(Co-Founder)Gordana Vunjak-Novakovic(Director)Elma Hawkins(Director)
BoardRobert Langer(Director)David Zhu(Director)
Co-investorsBeresford VenturesEMV CapitalHackensack Meridian Health Bear's DenKendall Capital PartnersPlum Alley InvestmentsTech Council Ventures
Haima Therapeutics is a pre-clinical stage biopharma company developing cell-inspired therapies for bleeding and blood-related diseases, with an initial focus on platelet-inspired treatments for active bleeding and bleeding risks from trauma, surgery, thrombocytopenia, and rare bleeding disorders.
BiotechMedical Devices
Anirban Sen Gupta(CTO)Michael Bruckman(CEO)Matthew Neal(CMO)Christa Pawlowski(COO and EVP of R&D)Timothy Pelura(Executive Chair)
Co-investorsCWRU Technology Ventures
Mammoth Bio develops technology to read and write the code of life, operating in the biotechnology sector.
BiotechDeep TechMedical DevicesBrisbane, US
Jennifer Doudna(Founder)inTrevor Martin(Co-founder, Chief Executive Officer)inJanice Chen(Co-founder, Chief Scientific Officer & President, Research)inLucas Harrington(Co-founder)inAshley Tehranchi(Executive Officer, Director)
BoardUrshit Parikh(Director)
Co-investors8VCBerkeley FrontierCALIFORNIA INNOVATIONDecheng CapitalForesite CapitalMayfield Fund+9 more
miRecule is a biotechnology company developing therapeutics, with programs focused on oncology.
BiotechHealthtechGaithersburg, US
Anthony Saleh(Executive Officer)Anthony D. Saleh(CEO)Dave Lemus(COO/CFO)
Co-investorsBrown and White VenturesPathway Bioventures
Palm Therapeutics develops palmitoylation-targeted drugs using its proprietary PalmReader screening platform to identify novel therapeutic molecules.
BiotechDeep TechMedical Devices
Andrew Rudd(Cofounder & CEO)
Peptilogics is a clinical-stage surgical therapeutics company developing zaloganan (PLG0206), a novel anti-biofilm drug to treat and prevent medical device-related infections such as prosthetic joint infections.
BiotechHealthtechMedical DevicesPittsburg, US
Jonathan Steckbeck(Executive Officer, Director)
BoardStephan Dietrich(Director)in
Co-investorsAAF Management Ltd.Alpha Wave GlobalAMR Action FundMountain State CapitalNarya CapitalRiverfront Ventures, LLC+2 more
Co-investorsBoston Harbor Angels
Scipher Medicine is a precision immunology company that uses molecular blood tests, such as PrismRA, to match patients with the most effective therapy for autoimmune diseases like rheumatoid arthritis.
AI & Machine LearningBiotechDigital Health
Joseph Loscalzo(Founder | Physician-in-Chief, Brigham and Women's Hospital)Albert-László Barabási(Founder | Professor, Harvard and Northeastern University)
Co-investorsaMoonKhosla VenturesB3 HoldingCobalt VenturesEcho Health VenturesHitachi Ventures+1 more
Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.
BiotechDigital HealthMedical Devices
Michael C. Bassik, Ph.D.(Scientific Founder)inEmile Nuwaysir, Ph.D.(Chairman & Chief Executive Officer)inJason Fontenot, Ph.D.(Chief Scientific Officer)
Co-investorsBrainstorm VenturesKhosla VenturesNeva Sgr.RA Capital
Valo builds an AI-driven drug discovery and development platform that combines real-world human data, causal inference, statistical genetics, and predictive chemistry to identify disease targets and engineer small-molecule compounds.
AI & Machine LearningBiotechDeep Tech
Co-investorsLifeforce Capital
BiotechHealthtech
Co-investorsClal Biotechnology IndustriesExSight VenturesLongitude CapitalThe Column Group
Exits · 1
IPOs and acquisitions across the tracked portfolioAbsciNASDAQ: ABSI
Portfolio news
latest coverage across their companiesAbsci · investing.com · Jun 25, 2026
Stylus Medicine · bio-itworld.com · May 30, 2025
Frequently asked questions
- How many investments has Tachyon Ventures made?
- Tachyon Ventures has 18 tracked investments, including 1 dated in the last 24 months.
- What stage does Tachyon Ventures invest at?
- Tachyon Ventures invests at the Pre-Seed, Seed, Series A stages.
- What sectors does Tachyon Ventures focus on?
- Tachyon Ventures focuses on Biotech, Deep Tech, Medical Devices.
- Where is Tachyon Ventures located?
- Tachyon Ventures is headquartered in Los Angeles, US.
- Who does Tachyon Ventures co-invest with?
- Tachyon Ventures most often shares deals with Creative Destruction Lab (CDL), Mission Biocapital, Pathway Bioventures, among 60 tracked co-investors.
Co-investors · 6
Plum Alley Investments is a venture investment firm that provides investors access to vetted early-stage technology opportunities and allocations, focusing on the convergence of computation, hardware innovation, and machine intelligence.
Mayfield is a venture capital firm that invests in early-stage consumer and marketplace companies, backing founders from inception through IPO.
Flucas Ventures is a solo GP fund led by Ashley Flucas, who simultaneously serves as COO of Summit Ventures while personally investing in 250-275+ startups and deploying over $75M through a syndicate of 2,000+ LPs in less than two years. The fund operates with true stage, sector, and geography agnosticism while democratizing access to top-tier venture deals by inviting diverse, nontraditional LPs to co-invest alongside marquee firms like Sequoia and Andreessen Horowitz.
Triatomic Capital is an investment firm focused on 'century defining' themes across advanced technology areas including AI infrastructure, semiconductors, materials, robotics, and energy.
Cantos Ventures is an early-stage venture firm founded in 2016 that provides initial capital and ongoing counsel to founders building deep technology in areas such as robotics, energy, space, defense, and advanced manufacturing.
Firms observed investing alongside Tachyon Ventures, from public investor directories. Shared companies are the overlap with Tachyon Ventures's recorded portfolio.
Similar investors
Amadeus Capital Partners is a technology investment firm that backs founders building complex, science-led and deep tech businesses, supporting them over the long term as they scale internationally.
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Future Positive Capital is a European deep-tech fund that ties its entire thesis to the Future Cones foresight framework, explicitly focusing on preferable futures and positioning itself as a futures-thinking, systems-change VC rather than a generic climate or impact fund. The firm hard-wires impact into its economics by contractually indexing more than 100% of partners' carried interest to portfolio companies achieving both financial and measurable impact outcomes, while specializing in capital-intensive, highly technical step-change solutions for planetary-scale problems like robotics for wind farm operations, large-scale carbon removal, and ecosystem restoration.